+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis



Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis



Medical Mycology 49(8): 834-847



Invasive pulmonary aspergillosis remains problematic in immunocompromised patient populations. We studied potential therapeutic options in a murine model of pulmonary aspergillosis in triamcinolone-suppressed DBA/2 mice infected intranasally with conidia from Aspergillus fumigatus. Mice were treated with liposomal-amphotericin B (AmBi; AmBisome), lipid-complexed amphotericin B (ABLC; Abelcet), voriconazole (VCZ), micafungin (MICA), caspofungin (CAS) or deoxycholate amphotericin B (AMBd) given alone or in combination. Monotherapy with AmBi, ABLC, AMBd, CAS or MICA had activity in prolonging survival; however, only AMBd or CAS reduced fungal burden in the lungs and kidneys. Combinations of AmBi plus CAS or MICA prolonged survival, but were not better than monotherapy. VCZ was ineffective and AMBd plus CAS showed a possible antagonism. AmBi or ABLC at higher dosages, or loading-doses of AmBi resulted in reduced survival. Histopathology showed increased incidence of serious renal and mild hepatic toxicity in triamcinolone-treated mice given an amphotericin B regimen compared to no or only triamcinolone (minimal renal changes occurred with CAS or VCZ with or without triamcinolone); suggestive of combined toxicity of triamcinolone and the amphotericin B in AmBi or ABLC. Infected treated mice showed progressive pulmonary disease including abscesses, angioinvasion and abundant intralesional fungi. High loading-doses of AmBi were associated with nephrosis and damage to other tissues. No monotherapy or combination regimen showed superiority for the treatment of pulmonary aspergillosis in corticosteroid suppressed mice and the potential for combined drug toxicity was enhanced in these mice. High dosages of lipid-formulated amphotericin B also proved unsatisfactory. Additional studies are needed to evaluate improved treatment.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056545564

Download citation: RISBibTeXText

PMID: 21539507

DOI: 10.3109/13693786.2011.577822


Related references

Therapeutic effects of recombinant forms of full-length and truncated human surfactant protein D in a murine model of invasive pulmonary aspergillosis. Molecular Immunology 46(11-12): 2363-2369, 2009

Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrobial Agents and ChemoTherapy 48(5): 1908-1911, 2004

Standardization of an experimental murine model of invasive pulmonary aspergillosis. Antimicrobial Agents and ChemoTherapy 50(10): 3501-3503, 2006

Murine model to follow hyphal development in invasive pulmonary aspergillosis. Applied Microbiology and Biotechnology 102(6): 2817-2825, 2018

Efficacy of ambruticin analogs in a murine model of invasive pulmonary aspergillosis. Antimicrobial Agents and ChemoTherapy 50(10): 3464-3466, 2006

In vivo pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 43: 445, 2003

Murine model of invasive pulmonary aspergillosis following an earlier stage, noninvasive Aspergillus infection. Journal of Clinical Microbiology 34(6): 1433-1439, 1996

Variation in virulence of Aspergillus fumigatus strains in a murine model of invasive pulmonary aspergillosis. Journal of Medical Microbiology 45(3): 186-191, 1996

Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis. Clinical and Experimental Immunology 148(2): 382-389, 2007

Protective role of lung surfactant protein D in a murine model of invasive pulmonary aspergillosis. Infection and Immunity 69(4): 2728-2731, 2001

Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. Journal of Infectious Diseases 190(8): 1464-1471, 2004

Pretreatment with itraconazole attenuates the efficacy of increasing amphotericin B dosages in a murine model of invasive pulmonary aspergillosis. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 41: 398, 2001

Synergistic effects of combination of FK463 with amphotericin B Enhanced efficacy in murine model of invasive pulmonary aspergillosis. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 40: 388, 2000

CCR7 deficiency on dendritic cells enhances fungal clearance in a murine model of pulmonary invasive aspergillosis. Journal of Immunology 183(8): 5171-5179, 2009

Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy 46(10): 3208-3214, 2002